- The FDA has approved the use of Edwards Lifesciences' (EW -3.0%) SAPIEN 3 transcatheter valve with the Alterra adaptive prestent for patients with severe pulmonary regurgitation.
- The use of Alterra makes up for variations in size and morphology of the right ventricular outflow tract allowing for a stable landing zone for the SAPIEN 3 valve.
- Sapien 3 with Alterra is indicated for pediatric and adult patients with severe pulmonary regurgitation who have a native or surgically repaired right ventricular outflow tract and are clinically indicated for surgical pulmonary valve replacement.
- Check out JP Morgan's recent upgrade of Edwards shares.
Edwards Lifesciences wins approval for Sapien 3 with Altera prestent
Recommended For You
About EW Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
EW | - | - |
Edwards Lifesciences Corporation |